Printer Friendly

SUMMIT TECHNOLOGY COMPLETES CLINICAL REQUIREMENTS FOR FDA PHASE III PHOTOREFRACTIVE KERATECTOMY (PRK) U.S. CLINICAL TRIALS

SUMMIT TECHNOLOGY COMPLETES CLINICAL REQUIREMENTS FOR FDA PHASE III
 PHOTOREFRACTIVE KERATECTOMY (PRK) U.S. CLINICAL TRIALS
 WALTHAM, Mass., Jan. 28 /PRNewswire/ -- Summit Technology, Inc. (NASDAQ: BEAM) announced today that clinical investigators using Summit's ExciMed(R) UV200LA laser system have treated the required cohort of patients necessary for completion of the company's Phase III photorefractive keratectomy (PRK) U.S. clinical trials.
 Investigators will continue to enroll patients in the PRK trials and will perform the required follow-up on the treated patients before submission of the company's application for commercial approval of its ExciMed UV200LA laser system for PRK. It is anticipated that the company will submit its application for premarket approval for PRK within 12-24 months.
 Summit believes that its investigators are the first to treat the complete cohort of patients required by the FDA for the completion of Phase III PRK U.S. clinical trials.
 Summit Technology, Inc. has established the leadership position in designing, manufacturing and marketing ophthalmic excimer laser systems. A major focus of the company's business is in ophthalmology where applications have been developed for the treatment of common vision disorders such as nearsightedness, farsightedness, astigmatism, glaucoma and certain corneal irregularities due to disease or injury. There are believed to be approximately 140 million people in the United States with refractive disorders. To date, over 10,000 patients have been treated worldwide by ophthalmologists using Summits ExciMed UV200LA excimer laser.
 -0- 1/28/92 R
 /CONTACT: Paula Rainville of Summit Technology, 617-890-1234/
 (BEAM) CO: Summit Technology, Inc. ST: Massachusetts IN: MTC SU:


SH -- NE003 -- 4082 01/28/92 09:18 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 28, 1992
Words:264
Previous Article:TOSCO DECLARES QUARTERLY DIVIDEND
Next Article:AMERICAN FILTRONA ANNOUNCES RESULTS; DECLARES DIVIDEND
Topics:


Related Articles
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
FDA ACCEPTS SUMMIT'S APPLICATION TO COMMERCIALLY MARKET EXCIMER LASER SYSTEMS FOR TREATMENT OF MYOPIA
SUMMIT TECHNOLOGY RECEIVES TWO FDA APPROVALS TO BEGIN PHASE III CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS & ASTIGMATISM
FDA OPHTHALMIC ADVISORY PANEL RECOMMENDS APPROVAL OF SUMMIT TECHNOLOGY'S EXCIMER LASER SYSTEM FOR PRK
SUMMIT RECEIVES AUTHORIZATION TO CONDUCT NEW CLINICAL TRIAL
EXCIMER LASER WINS FDA 'APPROVAL' LETTER; LASER PIONEER LAUDS DECISION
EXCIMER LASER SURGERY TO CORRECT MYOPIA APPROVED FOR U.S. MARKET
AUTONOMOUS TECHNOLOGIES CORPORATION RECEIVES FDA IDE APPROVAL TO BEGIN US CLINICAL TRIALS FOR LASER VISION CORRECTION
Autonomous' U.S. Phase II Six Month Results Show 90% 20/20

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters